Skip to content

ASNDBiotech for rare endocrine diseases

Ascendis Pharma

By

Updated

Not investment advice. Kevin may own this stock. How we value stocks

History
Price
$252.73
Intrinsic value
Intrinsic value from an AI estimate
Discount category
Below intrinsic value (AI estimate)
Analysts
Very bullish
Next earnings
Feb 12 · · estimated
Pick status
Research only

In short

Thesis
The market weighs the fast growth of YORVIPATH against doubts about how long it lasts and the BioMarin royalties on YUVIWEL, and more launches with EU approval of TransCon CNP through 2027 can lift its value.
Gap
Can close. The EU decision on TransCon CNP in Q4 2026, the launch in Germany in Q1 2027 and the pivotal data in infants in Q3 2027 show whether growth continues.

Company guidance: 2026 cash flow from operating activities of at least €600 million (, Q3 2026 release)

Price history

About

Ascendis Pharma A/S (ASND) is a Danish biopharmaceutical company based in Hellerup, near Copenhagen. Its TransCon technology releases a drug slowly in the body, so patients need fewer doses. It sells three products for rare endocrine diseases: YORVIPATH for hypoparathyroidism in adults, SKYTROFA, a once-weekly growth hormone, and YUVIWEL, a once-weekly treatment for children with achondroplasia that the FDA approved in February 2026.

Product revenue was €366 million in Q3 2026. Since April 20, 2026, the ordinary shares trade directly on Nasdaq in US dollars, in place of the ADSs. Ascendis reports in euros under IFRS and files 20-F and 6-K reports with the SEC.

Thesis

The price of Ascendis depends on how long the fast growth of YORVIPATH continues and on how much of the achondroplasia market YUVIWEL can take. Product revenue grew 89% in Q3 2026 to €366 million and the operating margin was 34%, so Ascendis now makes a profit and buys back shares. Investors cannot yet see how fast US demand for YORVIPATH will grow, because new patient demand there was steady, not rising. Ascendis also pays BioMarin royalties of 18% to 20% on YUVIWEL sales until May 2030.

The AI estimate rests on three conditions. YORVIPATH must keep its growth with launches in more countries. TransCon CNP must get EU approval in Q4 2026 and a good launch in Germany in Q1 2027. Cash flow from operating activities must reach at least €600 million in 2026, as the company expects.

The Q4 2026 report, expected in February 2027, and the pivotal data in infants in Q3 2027 are the next tests. If YORVIPATH growth slows, the value can fall a lot.

Valuation

AI estimate, checked by Kevin. How it is made

Show the method

The intrinsic value for Ascendis Pharma is an AI estimate from November 14, 2026. It is not an analyst's value. An AI research agent calculated it from the reports of Ascendis Pharma in euros that it files with the SEC on Forms 6-K and 20-F. The values are in US dollars per ordinary share, because the ordinary shares trade on Nasdaq in US dollars since April 20, 2026.

The method is a multiple of the 2028 operating profit after tax, discounted one year at 9%, plus net cash, divided by the diluted shares and converted to US dollars. The Q3 2026 release (6-K, November 12, 2026) gives product revenue of €366 million for Q3, with YORVIPATH at €291 million, SKYTROFA at €59 million and YUVIWEL at €16 million. It gives an operating profit of €125 million, or €156 million on a non-IFRS basis, a margin of 42%. It expects 2026 cash flow from operating activities of at least €600 million.

The interim report for the quarter (6-K, November 12, 2026) gives cash of €964.4 million, royalty funding liabilities of €302.1 million and lease liabilities of €145.7 million at September 30, 2026. It gives 66,400,738 shares, of which 805,528 were treasury shares, a dilution effect of 2,965,732 warrants and RSUs in Q3, and 1,204,695 shares that Ascendis bought back after September 30 for about $273.4 million. So the estimate uses 67,356,247 diluted shares and net cash of €269 million after the buybacks, royalty funding and leases. It does not add the deferred tax assets of €652 million, and it assumes that the multiples allow for them.

The estimate assumes the ECB reference rate of 1.1052 US dollars per euro of November 13, 2026. The 2028 revenue, the margins, a tax rate of 22% and the multiples are assumptions. The margins include the royalty to BioMarin of 20% in the US and 18% in some other countries on YUVIWEL until May 2030 (6-K, August 31, 2026). The low case assumes 2028 revenue of €2.0 billion, because YORVIPATH growth slows, an operating margin of 38% and 18 times.

It gives $165.04 per share. The base case assumes €2.6 billion, a margin of 45% and 22 times. It gives $306.66 per share. The high case assumes €3.1 billion, with a strong YUVIWEL launch, a margin of 50% and 25 times.

It gives $459.41 per share. The estimate assumes weights of 25%, 50% and 25%. The weighted intrinsic value is $309.44 per share. Patents on the TransCon products, US orphan drug exclusivity for YUVIWEL and a positive EU opinion for 10 years of orphan market exclusivity protect the products for a number of years, but Ascendis depends on three products, and other companies develop treatments for the same diseases.

Checkpoints

  1. Q4 2026 · est.Due this quarter
    EU decision on TransCon CNPThe European Commission approves TransCon CNP for children with achondroplasia in Q4 2026, and this passes; a delay past Q1 2027 or a refusal fails.
  2. Feb 12, 2027 · est.Pending
    Q4 2026 resultsCash flow from operating activities is at least €600 million for 2026 and product revenue grows again from Q3 2026, and this passes; a miss of either fails.
  3. Q3 2027 · est.Pending
    Pivotal data of TransCon CNP in infantsThe pivotal reACHin data in infants younger than two years show a clear growth benefit with good safety, and this passes; weak data or a safety problem fail.

Every passed and failed checkpoint across all picks

Recent events

  • November 12, 2026Ascendis reported Q3 2026 results. Product revenue grew 89% to €366 million: YORVIPATH €291 million, SKYTROFA €59 million and YUVIWEL €16 million. Operating profit was €125 million and net profit was €74 million, or €1.08 per diluted share. Ascendis expects 2026 cash flow from operating activities of at least €600 million. Through November 11, it bought back 1,998,999 shares in 2026 for $459 million.
  • October 16, 2026The CHMP of the European Medicines Agency recommended EU approval of TransCon CNP for children with achondroplasia from two years of age. Ascendis expects the European Commission decision in Q4 2026.
  • September 14, 2026The board approved a share repurchase program of up to $400 million. Ascendis also got back the rights to TransCon products in metabolic and cardiovascular diseases, including obesity, after the end of its collaboration with Novo Nordisk.
Show 5 older events
  • August 31, 2026Ascendis agreed a binding term sheet with BioMarin to settle all litigation about YUVIWEL. BioMarin gives a worldwide license, and Ascendis pays royalties on net sales of 20% in the US and 18% in the EU, South Korea and Brazil until May 20, 2030.
  • June 17, 2026Ascendis sold the rare pediatric disease priority review voucher that it got with the approval of YUVIWEL for $187.5 million in cash.
  • May 6, 2026All holders of the 2.25% convertible notes due 2028 converted their notes, and Ascendis delivered 3,635,813 ordinary shares.
  • April 20, 2026The ordinary shares started to trade directly on Nasdaq under the ticker ASND, and all ADSs were exchanged for ordinary shares.
  • February 27, 2026The FDA approved YUVIWEL under its Accelerated Approval Program to increase linear growth in children with achondroplasia from two years of age. It became available in the US on April 6, 2026, with orphan drug exclusivity.

Latest news and filings

Last earnings
November 12, 2026
Next earnings
Expected about February 12, 2027. The company has not confirmed the date.
  • 6-KInterim report for the period ended Sep 30, 2026Filed asnd-20260930
  • 6-KInterim report for the period ended Jun 30, 2026Filed asnd-20260630
  • 6-KInterim report for the period ended Mar 31, 2026Filed asnd-20260331
  • 20-FAnnual report for the period ended Dec 31, 2025Filed asnd-20251231

Every filing on SEC EDGAR (CIK 1612042)

Risks

  • YORVIPATH gave €740 million of the €921 million of product revenue in the first nine months of 2026. Slower patient growth, lower prices or a new competitor can reduce revenue and value a lot.
  • The FDA approved YUVIWEL under accelerated approval, so continued approval can depend on more data. The royalties of 18% to 20% to BioMarin until May 2030 reduce its margin, and new or better treatments from other companies can reduce demand.
  • Ascendis depends on third-party manufacturers, distributors and service providers. A supply or quality problem can stop sales of a product.
  • Pricing and reimbursement decisions by payers and health technology assessments in the US and Europe can limit the price and the number of patients.
  • Ascendis reports in euros, but most sales are in US dollars and the shares trade in US dollars. Currency changes can change the reported results.

Key statistics

Market cap
$16B
Shares of Dec 31, 2025
52-week range
$188.08 – $282.15
To Nov 13, 2026
Beta
0.40
Vs S&P 500, 5 years monthly, to Oct 30, 2026
Average volume
735K
3 months, to Nov 13, 2026

Balance sheet

Cash
€964M
Debt
€302M
Net cash
€662M

Cash against debt

Cash€964M
Debt€302M

debt covered by cash

At September 30, 2026, Ascendis had cash and cash equivalents of €964 million, up from €616 million at December 31, 2025. All 2.25% convertible notes due 2028 converted into 3,635,813 ordinary shares in May 2026, so there is no convertible debt.

Dividends

Ascendis Pharma does not pay a dividend.

Source: company filings and market data, read on November 13, 2026.

Questions about Ascendis Pharma

What does Ascendis Pharma do?

Ascendis Pharma A/S (ASND) is a Danish biopharmaceutical company based in Hellerup, near Copenhagen. Its TransCon technology releases a drug slowly in the body, so patients need fewer doses. Its market cap is $16B at the current price of $252.73.

When does Ascendis Pharma report earnings next?

This is an estimate: Ascendis Pharma may report on February 12, 2027. It last reported results on November 12, 2026.

Is Ascendis Pharma stock below its intrinsic value?

Ascendis Pharma stock is below intrinsic value. The source of the intrinsic value is: AI estimate. This is general information, not advice.

What changed recently at Ascendis Pharma?

The latest update is from November 12, 2026. Ascendis reported Q3 2026 results.

What are the main risks for Ascendis Pharma?

YORVIPATH gave €740 million of the €921 million of product revenue in the first nine months of 2026. The FDA approved YUVIWEL under accelerated approval, so continued approval can depend on more data. Ascendis depends on third-party manufacturers, distributors and service providers.

How much debt and cash does Ascendis Pharma have?

At September 30, 2026, Ascendis Pharma had €302M of debt and €964M of cash.

Does Ascendis Pharma pay a dividend?

No. Ascendis Pharma does not pay a dividend.

Similar companies

  • TAKTakeda PharmaceuticalShares: Regulation and courts
    Intrinsic value
    Far above intrinsic value (AI estimate)
    Gap
    Can close
  • INSMInsmedShares: Regulation and courts
    Intrinsic value
    Pricey (AI estimate)
    Gap
    Can close
  • NBIXNeurocrine BiosciencesShares: Regulation and courts
    Intrinsic value
    Below intrinsic value (AI estimate)
    Gap
    Can close
  • EWEdwards LifesciencesShares: Regulation and courts
    Intrinsic value
    Far above intrinsic value
    Gap
    Slow
  • ICLRICONShares: Regulation and courts
    Intrinsic value
    Close to intrinsic value
    Gap
    Can close

Loading your notes…

Read it all? Star ASND or pass, then go on to the next one.